Renal function in the long term after pediatric liver transplantation: Is there a need for protocol kidney biopsies?

Current Opinion in Organ Transplantation

Volumn 15, Issue 5, 2010, Pages 608-613

  Campbell, Kathleen M ^a   Bucuvalas, John C ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

long term outcomes; pediatric liver transplantation; renal function

Indexed keywords

CALCINEURIN INHIBITOR; CREATININE; CYCLOSPORIN; DACLIZUMAB; EVEROLIMUS; MULTIDRUG RESISTANCE PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

CHILD; CLINICAL PROTOCOL; CREATININE BLOOD LEVEL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE REDUCTION; DRUG EFFICACY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FUNCTION; LIVER TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; MONOTHERAPY; NEPHROTOXICITY; PEDIATRIC SURGERY; PHENOTYPE; POSTOPERATIVE COMPLICATION; RENAL PROTECTION; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADULT; AGE FACTORS; BIOPSY; CHILD; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY DISEASES; LIVER TRANSPLANTATION; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77957606199     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e32833da439     Document Type: Review

References (45)

1. Ojo AO, Held PJ, Port F.K., et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931-940.
2. Karie-Guigues S., Janus N, Saliba F., et al. Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study. Liver Transpl 2009; 15: 1083-1091.
3. Gonwa TA, Mai ML, Melton L.B., et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001; 72: 1934-1939.
4. Cohen AJ, Stegall MD, Rosen C.B., et al. Chronic renal dysfunction late after liver transplantation. Liver Transpl 2002; 8: 916-921.
5. Pawarode A, Fine DM, Thuluvath PJ Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 2003; 9: 741-747.
6. van Gelder T., Balk AH, Zietse R, et al. Renal insufficiency after heart transplantation: a case-control study. Nephrol Dial Transplant 1998; 13: 2322-2326.
7. USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease; 2004.
8. McDiarmid SV, Ettenger RB, Hawkins R.A., et al. The impairment of true glomerular filtration rate in long-term cyclosporine-treated pediatric allograft recipients. Transplantation 1990; 49: 81-85.
9. Bartosh SM, Alonso EM, Whitington PF Renal outcomes in pediatric liver transplantation. Clin Transplant 1997; 11 (5 PART 1): 354-360.
10. Herzog D, Martin S, Turpin S., Alvarez F. Normal glomerular filtration rate in long-term follow-up of children after orthotopic liver transplantation. Transplantation 2006; 81: 672-677.
11. Campbell KM, Yazigi N, Ryckman F.C., et al. High prevalence of renal dysfunction in long-term survivors after pediatric liver transplantation. J Pediatr 2006; 148: 475-480.
12. Berenson GS, Wattigney WA, Tracy R.E., et al. Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (the Bogalusa Heart Study). Am J Cardiol 1992; 70: 851-858.
13. Davis PH, Dawson JD, Riley W.A., Lauer RM Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: the Muscatine Study. Circulation 2001; 104: 2815-2819.
14. Gonwa TA. Hypertension and renal dysfunction in long-term liver transplant recipients. Liver Transpl 2001; 7 (11 SUPPL 1): S22-S26.
15. Berg UB, Ericzon BG, Nemeth A. Renal function before and long after liver transplantation in children. Transplantation 2001; 72: 631-637.
16. Campistol JM, Sacks SH Mechanisms of nephrotoxicity. Transplantation 2000; 69 (12 SUPPL.): SS5-SS10.
17. Laine J, Krogerus L, Fyhrquist F., et al. Renal function and histopathologic changes in children after liver transplantation. J Pediatr 1994; 125 (6 PART 1): 863-869.
18. Arora-Gupta N., Davies P, McKiernan P., Kelly DA The effect of long-term calcineurin inhibitor therapy on renal function in children after liver transplantation. Pediatr Transplant 2004; 8: 145-150.
19. Semhoun-Ducloux S., Ducloux D, Bresson-Hadni S, et al. Systemic hypertension and renal function in long-term liver transplant recipients on cyclosporine. Transplant Proc 2000; 32: 449-452.
20. Andrews WA, Arant BS, Fyock B, et al. The effect of cyclosporine A on long-term renal function in pediatric liver transplant recipients. Transplant Proc 1991; 23 (1 PART 2): 1452-1453.
21. McDiarmid SV, Ettenger RB, Fine R.N., et al. Serial decrease in glomerular filtration rate in long-term pediatric liver transplantation survivors treated with cyclosporine. Transplantation 1989; 47: 314-318.
22. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002; 39 (2 SUPPL. 1): S1-S266.
23. Burra P, Senzolo M, Masier A., et al. Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study. Dig Liver Dis 2009; 41: 350-356.
24. Barnard JB, Richardson S, Sheldon S., et al. The MDR1/ABCB1 gene, a high-impact risk factor for cardiac transplant rejection. Transplantation 2006; 82: 1677-1682.
25. Hebert MF, Dowling AL, Gierwatowski C, et al. Association between ABCB1 (multidrug resistance transporter) genotype and postliver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics 2003; 13: 661-674.
26. Hauser IA, Schaeffeler E, Gauer S., et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005; 16: 1501-1511.
27. Roy JN, Barama A, Poirier C., et al. Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genomics 2006; 16: 659-665.
28. Anglicheau D, Verstuyft C, Laurent-Puig P, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol 2003; 14: 1889-1896.
29. Macphee IA, Fredericks S, Tai T., et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002; 74: 1486-1489.
30. Fredericks S, Moreton M, Reboux S., et al. Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. Transplantation 2006; 82: 705-708.
31. Wei-lin W., Jing J, Shu-sen Z, et al. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. Liver Transpl 2006; 12: 775-780.
32. Hawwa AF, McKiernan PJ, Shields M, et al. Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant. Br J Clin Pharmacol 2009; 68: 413-421.
33. Smith HE, Jones JP 3rd, Kalhorn TF, et al. Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease. Pharmacogenet Genomics 2008; 18: 943-953.
34. McGuire BM, Rosenthal P, Brown C.C., et al. Long-term management of the liver transplant patient: recommendations for the primary care doctor. Am J Transplant 2009; 9: 1988-2003.
35. Tokunaga M, Kabashima N, Serino R., et al. Renoprotective effects of telmisartan in patients with advanced chronic kidney disease. Clin Nephrol 2010; 73: 139-146.
36. Bakris G. Are there effects of renin-angiotensin system antagonists beyond blood pressure control? Am J Cardiol 2010; 105 (1 SUPPL.): 21A-29A.
37. Ponton C, Vizcaino L, Tome S., et al. Improvement of renal function after conversion to mycophenolate mofetil combined with low-level calcineurin inhibitor in liver transplant recipients with chronic renal dysfunction. Transplant Proc 2010; 42: 656-659.
38. Beckebaum S, Klein CG, Sotiropoulos G.C., et al. Combined mycophenolate mofetil and minimal dose calcineurin inhibitor therapy in liver transplant patients: clinical results of a prospective randomized study. Transplant Proc 2009; 41: 2567-2569.
39. Neuberger JM, Mamelok RD, Neuhaus P, et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant 2009; 9: 327-336.
40. Castroagudin JF, Molina E, Romero R., et al. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction. Liver Transpl 2009; 15: 1792-1797.
41. Gerhardt T, Terjung B, Knipper P., et al. Renal impairment after liver transplantation: a pilot trial of calcineurin inhibitor-free vs. calcineurin inhibitor sparing immunosuppression in patients with mildly impaired renal function after liver transplantation. Eur J Med Res 2009; 14: 210-215.
42. Pons JA, Ramirez P, Revilla-Nuin B, et al. Immunosuppression withdrawal improves long-term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients. Clin Transplant 2009; 23: 329-336.
43. Cambaceres CG, Rojas L, Fernandez M.C., et al. Monitoring cyclosporine microemulsion at two hours post dosing in pediatric maintenance liver transplant recipients. Transplant Proc 2010; 42: 361-362.
44. Kim JY, Akalin E, Dikman S., et al. The variable pathology of kidney disease after liver transplantation. Transplantation 2010; 89: 215-221.
45. O'Riordan A., Dutt N, Cairns H., et al. Renal biopsy in liver transplant recipients. Nephrol Dial Transplant 2009; 24: 2276-2282.